Crisil Assigns Strong ESG Ratings to Cohance Lifesciences
Cohance Lifesciences Ltd 路 Others (Uncategorized) 路 06 Oct 2026, 8:54 pm
Crisil Assigns Strong ESG Ratings to Cohance Lifesciences Crisil ESG Ratings & Analytics Limited has voluntarily assigned an ESG rating of "Crisil ESG 61 (Strong)" and a Core ESG rating of "Crisil Core ESG 67 (Strong)" to Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) on 6th Oct'26. The ratings were independently evaluated based on publicly available information, with no formal engagement initiated by the company.
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... 路 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 12 Nov 2026
- Investors Meet 路 11 Nov 2026
- Transcript of Con call 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others 路 11 Nov 2026
- Investor Presentation 路 07 Nov 2026
- Update on USFDA inspection at Pashamylaram Manufacturing facility. 路 07 Nov 2026
